152P TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative

Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Prior results from a phase II study of E plus pembrolizumab (P) as a second-line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) led to promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report updated results from the PD-L1 negative (CPS <1) Cohort B of the TACTI-003 study in 1st line HNSCC (NCT04811027).

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.iotech.2024.100781
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

152P TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative

I. Braña, Marika Rasschaert, J. Christian, Frédéric Triebel et al.
Immuno-Oncology Technology
Cancer Immunotherapy and Biomarkers
article

152P TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative

I. Braña, Marika Rasschaert, J. Christian, Frédéric Triebel, Robert L. Metcalf, Sebastian M. Dieter, Ainara Soria Rivas, Simon Laban, T-E. Ciuleanu, C. Mueller, Martin Förster, C.A. Kristensen, M. Covela
article en

Abstract

Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Prior results from a phase II study of E plus pembrolizumab (P) as a second-line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) led to promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report updated results from the PD-L1 negative (CPS <1) Cohort B of the TACTI-003 study in 1st line HNSCC (NCT04811027).

Immuno-Oncology TechnologyVol. 24
Hebron University (PS), Nottingham University Hospitals NHS Trust (GB), University College London Hospitals NHS Foundation Trust (GB), Copenhagen University Hospital (DK), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), Antwerp University Hospital (BE), Vall d'Hebron Institut de Recerca (ES), National Center for Tumor Diseases (DE), Vall d'Hebron Hospital Universitari (ES), The Christie NHS Foundation Trust (GB), TrueBinding (United States) (US), Immutep (Germany) (DE), Hospital Universitario Lucus Augusti (ES), Hospital Universitario Ramón y Cajal (ES), University College London (GB)
Zero hunger
Openalex Percentile: Top 60%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.